JP5888853B2 - 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置 - Google Patents

4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置 Download PDF

Info

Publication number
JP5888853B2
JP5888853B2 JP2010510505A JP2010510505A JP5888853B2 JP 5888853 B2 JP5888853 B2 JP 5888853B2 JP 2010510505 A JP2010510505 A JP 2010510505A JP 2010510505 A JP2010510505 A JP 2010510505A JP 5888853 B2 JP5888853 B2 JP 5888853B2
Authority
JP
Japan
Prior art keywords
imatinib
methoxy
leukemia
bcrabl
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010510505A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529038A5 (https=
JP2010529038A (ja
Inventor
ベッカー ヘウェス,
ベッカー ヘウェス,
Original Assignee
ワイス・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39639071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5888853(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ワイス・エルエルシー filed Critical ワイス・エルエルシー
Publication of JP2010529038A publication Critical patent/JP2010529038A/ja
Publication of JP2010529038A5 publication Critical patent/JP2010529038A5/ja
Application granted granted Critical
Publication of JP5888853B2 publication Critical patent/JP5888853B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2010510505A 2007-06-01 2008-05-30 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置 Active JP5888853B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93265007P 2007-06-01 2007-06-01
US60/932,650 2007-06-01
PCT/US2008/065215 WO2008150957A2 (en) 2007-06-01 2008-05-30 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2014016309A Division JP2014111629A (ja) 2007-06-01 2014-01-31 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置
JP2015229117A Division JP2016074700A (ja) 2007-06-01 2015-11-24 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置

Publications (3)

Publication Number Publication Date
JP2010529038A JP2010529038A (ja) 2010-08-26
JP2010529038A5 JP2010529038A5 (https=) 2016-01-14
JP5888853B2 true JP5888853B2 (ja) 2016-03-22

Family

ID=39639071

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010510505A Active JP5888853B2 (ja) 2007-06-01 2008-05-30 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置
JP2014016309A Pending JP2014111629A (ja) 2007-06-01 2014-01-31 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置
JP2015229117A Pending JP2016074700A (ja) 2007-06-01 2015-11-24 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014016309A Pending JP2014111629A (ja) 2007-06-01 2014-01-31 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置
JP2015229117A Pending JP2016074700A (ja) 2007-06-01 2015-11-24 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置

Country Status (23)

Country Link
US (1) US11103497B2 (https=)
EP (4) EP2152267A2 (https=)
JP (3) JP5888853B2 (https=)
KR (1) KR101493543B1 (https=)
CN (1) CN101686973B (https=)
AU (1) AU2008260070B9 (https=)
BR (1) BRPI0812355A2 (https=)
CA (3) CA2964162C (https=)
CL (1) CL2008001577A1 (https=)
CY (2) CY1115251T1 (https=)
DK (2) DK2478905T3 (https=)
ES (2) ES2881391T3 (https=)
HU (1) HUE055524T2 (https=)
IL (1) IL202407A0 (https=)
MX (1) MX2009013069A (https=)
PA (1) PA8782301A1 (https=)
PL (2) PL2478905T3 (https=)
PT (2) PT2478905E (https=)
RU (1) RU2464026C2 (https=)
SI (2) SI2478905T1 (https=)
TW (1) TW200908982A (https=)
WO (1) WO2008150957A2 (https=)
ZA (1) ZA200908480B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016074700A (ja) * 2007-06-01 2016-05-12 ワイス・エルエルシー 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG192769A1 (en) 2011-03-04 2013-09-30 Glaxosmithkline Ip No 2 Ltd Amino-quinolines as kinase inhibitors
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
RU2662810C2 (ru) 2013-02-21 2018-07-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Хиназолины в качестве ингибиторов киназы
KR101733665B1 (ko) 2015-05-06 2017-05-10 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 진세노사이드 F1 또는 Rg3을 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물
JP2022544700A (ja) * 2019-08-22 2022-10-20 バイオヘイブン・セラピューティクス・リミテッド 筋萎縮性側索硬化症および関連障害の治療のためにtdp-43に結合する分子
CN115944636A (zh) * 2022-11-01 2023-04-11 华南师范大学 博舒替尼在抑制i-motif结构上的应用
WO2025024311A2 (en) * 2023-07-21 2025-01-30 Icahn School Of Medicine At Mount Sinai G9a/glp inhibitors and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
AU2002245296B2 (en) * 2001-01-25 2006-12-21 Bristol-Myers Squibb Company Methods of administering epothilone analogs for the treatment of cancer
PT2017335E (pt) 2001-10-05 2011-03-02 Novartis Ag Domínios da cinase abl mutados
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20050010780A1 (en) * 2003-07-09 2005-01-13 Kane John Richard Method and apparatus for providing access to personal information
EP1680119A1 (en) * 2003-11-06 2006-07-19 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
NL1031674C2 (nl) 2005-04-25 2007-04-26 Pfizer Antilichamen tegen myostatine.
DE602006014540D1 (en) * 2005-05-16 2010-07-08 Irm Llc Pyrrolopyridinderivate als proteinkinaseinhibitoren
EP1904654A2 (en) 2005-07-15 2008-04-02 Brystol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant src kinase polypeptides
BRPI0616923A2 (pt) 2005-10-06 2011-07-05 Lilly Co Eli anticorpos monoclonais, seus usos e composição farmacêutica
EP1948820A2 (en) * 2005-11-04 2008-07-30 Bristol-Myers Squibb Pharma Company T315a and f317i mutations of bcr-abl kinase domain
CA2964162C (en) 2007-06-01 2019-12-31 Wyeth Llc Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016074700A (ja) * 2007-06-01 2016-05-12 ワイス・エルエルシー 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置

Also Published As

Publication number Publication date
SI3002009T1 (sl) 2021-09-30
RU2009144128A (ru) 2011-07-20
RU2464026C2 (ru) 2012-10-20
PA8782301A1 (es) 2009-01-23
IL202407A0 (en) 2010-06-30
HK1142812A1 (en) 2010-12-17
EP3002009A3 (en) 2016-07-06
BRPI0812355A2 (pt) 2015-01-27
CN101686973A (zh) 2010-03-31
CA2964162C (en) 2019-12-31
CY1124391T1 (el) 2022-07-22
EP3002009A2 (en) 2016-04-06
TW200908982A (en) 2009-03-01
MX2009013069A (es) 2010-03-17
EP2152267A2 (en) 2010-02-17
DK3002009T3 (da) 2021-08-02
ES2881391T3 (es) 2021-11-29
CY1115251T1 (el) 2017-01-04
CA2688467C (en) 2015-05-12
JP2010529038A (ja) 2010-08-26
EP2777704A2 (en) 2014-09-17
AU2008260070B2 (en) 2011-08-18
KR20100017983A (ko) 2010-02-16
CA2868899C (en) 2017-06-13
EP2478905A3 (en) 2013-01-16
ES2477567T3 (es) 2014-07-17
JP2016074700A (ja) 2016-05-12
AU2008260070B9 (en) 2012-01-19
ZA200908480B (en) 2010-08-25
US11103497B2 (en) 2021-08-31
CA2688467A1 (en) 2008-12-11
EP3002009B1 (en) 2021-07-07
CA2964162A1 (en) 2008-12-11
HUE055524T2 (hu) 2021-11-29
PL2478905T3 (pl) 2014-10-31
WO2008150957A3 (en) 2009-08-06
PL3002009T3 (pl) 2021-12-13
KR101493543B1 (ko) 2015-02-13
US20080318971A1 (en) 2008-12-25
SI2478905T1 (sl) 2014-07-31
CA2868899A1 (en) 2008-12-11
EP2478905B1 (en) 2014-05-14
AU2008260070A1 (en) 2008-12-11
PT2478905E (pt) 2014-07-16
JP2014111629A (ja) 2014-06-19
CN101686973B (zh) 2013-06-19
DK2478905T3 (da) 2014-06-30
WO2008150957A2 (en) 2008-12-11
EP2777704A3 (en) 2015-01-21
CL2008001577A1 (es) 2008-07-25
PT3002009T (pt) 2021-08-02
EP2478905A2 (en) 2012-07-25

Similar Documents

Publication Publication Date Title
JP5888853B2 (ja) 4−アミノキノリン−3−カルボニトリルを使用するイマチニブ耐性白血病の処置
US7919625B2 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
CN119733053A (zh) Kras g12c抑制剂与米托蒽醌的药物组合及其用途
CN112426424A (zh) 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗her2突变癌症药物中的用途
JP7640033B2 (ja) ピリド[1,2-a]ピリミジノン類似体の使用
TWI872311B (zh) 一種吡啶并[1,2-a]嘧啶酮類似物的應用
HK1142812B (en) Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles
WO2005047259A1 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
WO2008060283A1 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
JPH10236953A (ja) p21誘導剤

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20110124

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110525

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20121121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130708

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130808

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140131

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140325

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140418

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141216

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151124

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20151124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160216

R150 Certificate of patent or registration of utility model

Ref document number: 5888853

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250